Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections

Trial Profile

Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2018

At a glance

  • Drugs Posaconazole (Primary) ; Posaconazole (Primary)
  • Indications Mycoses
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 15 Sep 2018 to 23 Nov 2018.
    • 09 Apr 2018 Planned primary completion date changed from 15 Sep 2018 to 23 Nov 2018.
    • 25 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top